The Effect of Intravenous Magnesium Sulfate on Intraocular Pressure Following Tracheal Intubation

This study has been completed.
Sponsor:
Information provided by:
Shiraz University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01241175
First received: November 15, 2010
Last updated: NA
Last verified: March 2009
History: No changes posted
  Purpose

The aim of this study is to assess the effect of preoperatively administered intra venous magnesium sulfate in attenuating pressure response to laryngoscopy and endotracheal intubation in adult patients scheduled for elective non ocular surgery


Condition Intervention Phase
Increased Intra Ocular Pressure (IOP)
Drug: Magnesium Sulfate
Drug: normal saline
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Masking: Double Blind (Caregiver, Outcomes Assessor)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Shiraz University of Medical Sciences:

Primary Outcome Measures:
  • Intra ocular pressure [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • blood pressure,heart rate [ Designated as safety issue: No ]

Arms Assigned Interventions
Experimental: magnesium sulfate Drug: Magnesium Sulfate
Placebo Comparator: normal saline Drug: normal saline

  Eligibility

Ages Eligible for Study:   18 Years to 38 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 to 38 years old
  • ASA I
  • scheduled for elective ENT ambulatory surgeries under general anesthesia

Exclusion Criteria:

  • specific major hepatic, renal and cardio-vascular disease
  • known to have allergic reaction to magnesium sulphate or other drugs , -hypermagnesemia
  • hypocalcemia
  • anuria
  • heart block
  • pregnancy
  • any degree of renal insufficiency
  • digitalised patients
  • positive history of glaucoma or intra ocular hypertension
  • refused to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01241175

Locations
Iran, Islamic Republic of
Shiraz University of Medical Sciences
Shiraz, Fars, Iran, Islamic Republic of
Sponsors and Collaborators
Shiraz University of Medical Sciences
Investigators
Study Director: Hilda Mahmoudi, M.D Shiraz University of Medical Sciences
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01241175     History of Changes
Other Study ID Numbers: 4286
Study First Received: November 15, 2010
Last Updated: November 15, 2010
Health Authority: Iran: Ministry of Health

Keywords provided by Shiraz University of Medical Sciences:
IOP
ophthalmic anesthesia
magnesium sulfate

Additional relevant MeSH terms:
Glaucoma
Eye Diseases
Ocular Hypertension
Magnesium Sulfate
Analgesics
Anesthetics
Anti-Arrhythmia Agents
Anticonvulsants
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Sensory System Agents
Therapeutic Uses
Tocolytic Agents

ClinicalTrials.gov processed this record on October 30, 2014